7000 Shoreline Court, Suite 201
South San Francisco
78 articles with Tricida, Inc.
Dr. Parsell will lead Tricida’s clinical development of TRC101
Tricida Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Tricida, Inc. (NASDAQ: TCDA), a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with...
It’s been a pretty good year for biotech initial public offerings (IPOs), with two Bay Area biotechs marking numbers eight and nine for the area.
Tricida, a late-stage biotech company developing therapies for conditions associated with chronic kidney disease (CKD), filed late Monday with the Securities and Exchange Commission to raise up to $150 million in an initial public offering.
Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients With Metabolic Acidosis
Tricida, Inc., a late-stage pharmaceutical company, announced results from its pivotal Phase 3 double-blind, randomized, placebo-controlled, multi-center Phase 3 clinical trial, TRCA-301, in 217 chronic kidney disease (CKD) patients with metabolic acidosis.
Ms. Falberg is a seasoned pharmaceutical industry executive with extensive leadership and finance expertise.
Tricida, Inc. announced today that it has entered into a $100 million venture debt facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customizing debt financing for companies in the life sciences and technology-related markets.
Tricida Announces Hiring of Jeroen van Beek, Ph.D., as Chief Commercial Officer and Senior Vice President
Dr. van Beek will lead Tricida’s commercial planning and operations functions.
Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101.
Tricida Announces Podium Presentation at ASN Kidney Week 2017 of TRC101 Phase I/II Study Results in Patients With Metabolic Acidosis Associated with Chronic Kidney Disease
Tricida today announced that David A. Bushinsky, M.D., will deliver a podium presentation at the ASN Annual Kidney Week meeting, taking place November 1-5, 2017 in New Orleans, on the results of Tricida’s successful Phase 1/2 study of TRC101.
Tricida Initiates Phase III Study Of TRC101 For The Treatment Of Metabolic Acidosis Associated With Chronic Kidney Disease
Tricida Announces Positive Topline Phase I/II Clinical Trial Results For TRC101 In 135 Subjects With Chronic Kidney Disease And Metabolic Acidosis
Tricida Announces FDA Acceptance Of Investigational New Drug Application For Lead Candidate TRC101 And Hiring Of Claire Lockey As Chief Development Officer And Edward J. Hejlek As General Counsel